ROMOSOZUMAB

Brand name:

• Evenity®

Pharmaceutical company:

Amgen Australia Pty Limited

Condition/indication:
(therapeutic use)

• Osteoporosis

PBAC Submission type:

Change to PBS listing (Standard Re-entry Pathway)

Comment:

No further action, please see ROMOSOZUMAB link in Related medicines below.

Public Summary Document:

PBAC Public Summary Documents – March 2023

Related medicines:

• ROMOSOZUMAB
• ROMOSOZUMAB
• ROMOSOZUMAB
• ROMOSOZUMAB

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

06/06/2023

Lodgement of required documentation:

13/06/2023

Acceptance of complete documentation:

Not Accepted

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---